SpringWorks Therapeutics nabs $103 mln Series A

SpringWorks Therapeutics, a developer of potential new treatments for underserved patient communities, has launched with $103 million in Series A financing. The investors were Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer and LifeArc.

North AmericaUSBriefs